Wegovy-maker Novo Nordisk cuts outlook again as obesity drug sales slow – Reuters

  1. Wegovy-maker Novo Nordisk cuts outlook again as obesity drug sales slow  Reuters
  2. Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount  CNBC
  3. Should You Buy Novo Nordisk Stock Before the Huge Investor Update?  Nasdaq
  4. Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight  Reuters
  5. Novo Nordisk’s sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues  Yahoo Finance

Continue Reading